An Interview from the 2015 American Society of Hematology Annual Meeting with Dr. Richard Furman on the Emerging Role of Novel Agents in CLL
This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.
Dr. Jeff Jones out of Ohio State University tells us in this interview from ASH 2015 that there is hope for those who relapse after ibrutinib and idelalisib.
Take Away Points:
- Prior studies have shown very poor prognosis for those who need to stop their idelalisib and ibrutinib.
- Relapses may be different and less aggressive after idelalisib compared to idelalisib.
- Venetoclax offers encouraging results for these difficult to treat populations with the expected toxicity.
- Responses to venetoclax in this group may be rapid and deep, but we don’t yet know how durable the responses will prove to be.
Dr. Jones muses at the end of the interview that perhaps combination therapies will prove better than sequential therapy for those us with high-risk disease.
Only more clinical trials will give us those answers.
Here is my interview
Here is a link to the actual abstract if you want to read the data yourself.
Brian Koffman, MD 8/23/16
Related posts